rpcardioRational Pharmacotherapy in CardiologyРациональная Фармакотерапия в Кардиологии1819-64462225-3653«SILICEA-POLIGRAF» LLC10.20996/1819-6446-2008-4-2-81-84rpcardio-1097Research ArticleCURRENT QUESTIONS OF CLINICAL PHARMACOLOGYАКТУАЛЬНЫЕ ВОПРОСЫ КЛИНИЧЕСКОЙ ФАРМАКОЛОГИИBETA-ADRENOBLOCKERS AND PLATELET AGGREGATION. CARVEDILOLБЕТА-АДРЕНОБЛОКАТОРЫ И АГРЕГАЦИЯ ТРОМБОЦИТОВ. КАРВЕДИЛОЛЗакироваА. Н.ZakirovaA. N.ЗарудийФ. С.ZarudijF. S.ГарифуллинБ. Н.GarifullinB. N.Башкирский государственный медицинский университет Росздрава, УфаРоссияBashkiria state medical university, UfaRussian Federation200829012016428184Copyright © Zakirova A.N., Zarudij F.S., Garifullin B.N., 20162016Закирова А.Н., Зарудий Ф.С., Гарифуллин Б.Н.Zakirova A.N., Zarudij F.S., Garifullin B.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rpcardio.online/jour/article/view/1097

Approaches evolution to studying of beta-blockers influence on platelet aggregation is reviewed. The current view on of beta-blocker antiplatelet effects is presented on the basis of physical and chemical drug properties (water repellency, dipole moment, molecular mass). Trail results on carvedilol influence on platelet aggregation are focused.

Рассмотрена эволюция подходов к изучению влияния бета-блокаторов на агрегацию тромбоцитов. Представлена современная концепция, интерпретирующая антиагрегационный потенциал бета-блокаторов с позиций физико-химических свойств препаратов, таких как гидрофобность, дипольный момент, молекулярная масса. Обобщены данные исследований по влиянию карведилола на агрегацию тромбоцитов.

бета-блокаторыагрегация тромбоцитовкарведилолbeta-blockersplatelet aggregationcarvedilolReferencesЗадионченко В.С., Яковлева М.С., Шехян Г.Г., Миронова М.А. Применение карведилола в комплексной терапии больных инфарктом миокарда с зубцом Q. Тер арх 2005;(8):14-9.Задионченко В.С., Яковлева М.С., Шехян Г.Г., Миронова М.А. Применение карведилола в комплексной терапии больных инфарктом миокарда с зубцом Q. Тер арх 2005;(8):14-9.Новиков Т.А., Зарудий Ф.А., Закирова А.Н. Влияние небиволола на агрегацию тромбоцитов и противосвертывающую систему. Кардиология 2003;(7):70-6Новиков Т.А., Зарудий Ф.А., Закирова А.Н. Влияние небиволола на агрегацию тромбоцитов и противосвертывающую систему. Кардиология 2003;(7):70-6Преображенский Д.В., Сидоренко Б.А., Дедова И.С., Тарыкина Е.В. Блокаторыβ-адренорецепторов в лечении сердечно-сосудистых заболеваний: место карведилола. Кардиология 2006;(12): 63-72Преображенский Д.В., Сидоренко Б.А., Дедова И.С., Тарыкина Е.В. Блокаторыβ-адренорецепторов в лечении сердечно-сосудистых заболеваний: место карведилола. Кардиология 2006;(12): 63-72Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71– 86Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71– 86Bartsch W, Sponer G, Strein K, et al. Pharmacological characteristics of the stereoisomers of carvedilol. Eur J Clin Pharmacol 1990; 38 Suppl 2:S104-7.Bartsch W, Sponer G, Strein K, et al. Pharmacological characteristics of the stereoisomers of carvedilol. Eur J Clin Pharmacol 1990; 38 Suppl 2:S104-7.Clappers N, Brouwer MA, Verheugt F. Antiplatelet treatment for coronary heart disease. Heart 2007; 93(2):258-65Clappers N, Brouwer MA, Verheugt F. Antiplatelet treatment for coronary heart disease. Heart 2007; 93(2):258-65Cheng H.Y., Randall C.S., Holl W.W. et al. Carvedilol-liposome interaction: evidence for strong association with hydrophobic region of lipid bilayers. Biochim Biophys Acta 1996;1284(1):20-8Cheng H.Y., Randall C.S., Holl W.W. et al. Carvedilol-liposome interaction: evidence for strong association with hydrophobic region of lipid bilayers. Biochim Biophys Acta 1996;1284(1):20-8Cheng J, Kamiya K, Kodama I. Carvedilol: molecular and cellular basis for its multifaceted therapeutic potential. Cardiovasc Drugs Rev 2001; 19(2):152-71Cheng J, Kamiya K, Kodama I. Carvedilol: molecular and cellular basis for its multifaceted therapeutic potential. Cardiovasc Drugs Rev 2001; 19(2):152-71Dash D, Rao K. Effect of propranolol on platelet signal transduction. Biochem J 1995;309:99-104Dash D, Rao K. Effect of propranolol on platelet signal transduction. Biochem J 1995;309:99-104Falciani M., Rinaldi B., D’Agostino B. et al. Effects of nebivolol on human platelet aggregation. J Cardiovasc Pharmacol 2001;38:922-9Falciani M., Rinaldi B., D’Agostino B. et al. Effects of nebivolol on human platelet aggregation. J Cardiovasc Pharmacol 2001;38:922-9Feuerstein G, Yue T-L, Ma X, et al. Novel mechanisms in the treatment of heart failure: Inhibition of oxygen radicals and apoptosis by carvedilol. Prog Cardiovasc Dis 1998;41:17–24Feuerstein G, Yue T-L, Ma X, et al. Novel mechanisms in the treatment of heart failure: Inhibition of oxygen radicals and apoptosis by carvedilol. Prog Cardiovasc Dis 1998;41:17–24Frishman W.H., Weksler B., Christodoulou J.P. et al. Reversal of abnormal platelet aggregability and change in exercise tolerance in patients with angina pectoris following oral propranolol. Circulation 1974; 50:887- 96Frishman W.H., Weksler B., Christodoulou J.P. et al. Reversal of abnormal platelet aggregability and change in exercise tolerance in patients with angina pectoris following oral propranolol. Circulation 1974; 50:887- 96Fuster V., Badimon L., Badimon J.J. et al. The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N Engl J Med 1992;326:310–8Fuster V., Badimon L., Badimon J.J. et al. The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N Engl J Med 1992;326:310–8Gasser JA, Betterridge DJ. Comparison of the effects of carvedilol, propranolol, and verapamil on in vitro platelet function in healthy volunteers. J Сardiovasc Pharmacol 1991; 18 Suppl 4:S29-34Gasser JA, Betterridge DJ. Comparison of the effects of carvedilol, propranolol, and verapamil on in vitro platelet function in healthy volunteers. J Сardiovasc Pharmacol 1991; 18 Suppl 4:S29-34Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest 2005;115:3378–84Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest 2005;115:3378–84Girke S, Mohr K, Schrape S. Comparison between the cationic amphiphilic drugs to affect phospholipid membranes and to depress cardiac function. Biochem Pharmacol 1989;38:2487-96Girke S, Mohr K, Schrape S. Comparison between the cationic amphiphilic drugs to affect phospholipid membranes and to depress cardiac function. Biochem Pharmacol 1989;38:2487-96Hansen K.W., Klysner R., Geisler A. et al. Platelet aggregation and betablockers. Lancet 1982; 1(8265):224-5Hansen K.W., Klysner R., Geisler A. et al. Platelet aggregation and betablockers. Lancet 1982; 1(8265):224-5Kalimowski L., Dobrucci L.W., Szczepanska-Konkel M. et al. Third-generation beta-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypetensive action. Circulation 2003; 107(21):2747-52.Kalimowski L., Dobrucci L.W., Szczepanska-Konkel M. et al. Third-generation beta-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypetensive action. Circulation 2003; 107(21):2747-52.Kerry R, Scrutton MC, Wallis RB. Beta-adrenoceptor antagonists and human platelets: relation of effects to lipid solubility. Biochem Pharmacol 1984; 33(16):2615-22Kerry R, Scrutton MC, Wallis RB. Beta-adrenoceptor antagonists and human platelets: relation of effects to lipid solubility. Biochem Pharmacol 1984; 33(16):2615-22Knight CJ, Panesar M, Wilson DJ, et al. Different effects of calcium antagonists, nitrates, and beta-blockers on platelet function. Possible importance for the treatment of unstable angina. Circulation 1997; 95(1):125-32Knight CJ, Panesar M, Wilson DJ, et al. Different effects of calcium antagonists, nitrates, and beta-blockers on platelet function. Possible importance for the treatment of unstable angina. Circulation 1997; 95(1):125-32Kurosaki K, Ikeda U, Maeda Y, et al. Carvedilol stimulates nitric oxide synthesis in rat cardiac myocytes. J Molecular and Cellular Cardiology 2000;32(2):333-9Kurosaki K, Ikeda U, Maeda Y, et al. Carvedilol stimulates nitric oxide synthesis in rat cardiac myocytes. J Molecular and Cellular Cardiology 2000;32(2):333-9Nosál’ R, Jančinová V, Ondriaš K, et al. The interaction of beta-adrenoceptor blocking drugs with platelet aggregation, calcium displacement and fluidization of the membrane. Biochim Biophys Acta 1985; 821:217-28Nosál’ R, Jančinová V, Ondriaš K, et al. The interaction of beta-adrenoceptor blocking drugs with platelet aggregation, calcium displacement and fluidization of the membrane. Biochim Biophys Acta 1985; 821:217-28Pečivová J, Mačičková T, Lojek A. In vitro effect of carvedilol on professional phagocytes. Pharmacology 2007;79:86-92Pečivová J, Mačičková T, Lojek A. In vitro effect of carvedilol on professional phagocytes. Pharmacology 2007;79:86-92Petrikova M., Jančinová V., Nosál’ R. et al. Carvedilol--a beta-blocker with considerable antiaggregatory effect on human blood platelets. Bratisl Lek Listy 2005;106(1):20-5Petrikova M., Jančinová V., Nosál’ R. et al. Carvedilol--a beta-blocker with considerable antiaggregatory effect on human blood platelets. Bratisl Lek Listy 2005;106(1):20-5Punda A., Polić S., Rumboldt Z. et al. Effects of atenolol and propranolol on platelet aggregation in moderate essential hypertension: randomized crossover trial. Croat Med J 2005;46(2):219-24Punda A., Polić S., Rumboldt Z. et al. Effects of atenolol and propranolol on platelet aggregation in moderate essential hypertension: randomized crossover trial. Croat Med J 2005;46(2):219-24Butler S, Wang R, Wunder SL, Cheng HY, Randall CS. Perturbing effects of carvedilol on a model membrane system: role of lipophilicity and chemical structure. Biophys Chem 2006;119:307-15Butler S, Wang R, Wunder SL, Cheng HY, Randall CS. Perturbing effects of carvedilol on a model membrane system: role of lipophilicity and chemical structure. Biophys Chem 2006;119:307-15Weksler B, Gillik M, Pink J. Effect of propranolol on platelet function. Blood 1977; 49:185-96Weksler B, Gillik M, Pink J. Effect of propranolol on platelet function. Blood 1977; 49:185-96Winther K, Gleerup G, Hedner T. Platelet function and fibrinolytic activity in hypertension: differential effects of calcium antagonists and betaadrenergic receptor blockers. J Cardiovasc Pharmacol 1991; 18 Suppl 9:S41-4.Winther K, Gleerup G, Hedner T. Platelet function and fibrinolytic activity in hypertension: differential effects of calcium antagonists and betaadrenergic receptor blockers. J Cardiovasc Pharmacol 1991; 18 Suppl 9:S41-4.Winther K., Knudsen J.B., Gormsen J. et al. Effect of metoprolol and propranolol on platelet aggregation and cAMP level in hypertensive patients. Eur J Clin Pharmacol 1986;29:561-4Winther K., Knudsen J.B., Gormsen J. et al. Effect of metoprolol and propranolol on platelet aggregation and cAMP level in hypertensive patients. Eur J Clin Pharmacol 1986;29:561-4Winther K, Trap-Jensen J. Effects of three beta-blockers with different pharmacodynamic properties on platelet aggregation and platelet and plasma cyclic AMP. Eur J Clin Pharmacol 1988; 35:17-20Winther K, Trap-Jensen J. Effects of three beta-blockers with different pharmacodynamic properties on platelet aggregation and platelet and plasma cyclic AMP. Eur J Clin Pharmacol 1988; 35:17-20

The authors declare that there are no conflicts of interest present.